Vimarsana
Biggest News Aggregation in the World

Ruby Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ruby Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ruby Study Today - Breaking & Trending Today

FDA Grants Priority Review to Dostarlimab Plus Chemo for dMMR/MSI-H Endometrial Cancer - Vimarsana News

FDA Grants Priority Review to Dostarlimab Plus Chemo for dMMR/MSI-H Endometrial Cancer

Published: June 6, 2023

The FDA has accepted and granted priority review to a supplemental biologics license application seeking the approval of dostarlimab plus chemotherapy for use in adult patients with mismatch repair–deficient/microsatellite instability–high primary advanced or recurrent endometrial cancer.

Source: onclive.com
Related Topics:
New England JournalDostarlimab Plus ChemotherapyEndometrial CancerMsi HGynecologic CancerPriority ReviewMismatch Repair DeficientMicrosatellite Instability HighRuby StudyRuby Engot Eng Gog3031 Nsgo New England Journal Of Medicine
Dostarlimab in Combination with Chemotherapy for the Treatment of Primary Advanced or Recurrent Endometrial Cancer: A Placebo-Controlled Randomized Phase 3 Trial (ENGOT-EN6-NSGO/GOG-3031/RUBY) - Vimarsana News

Dostarlimab in Combination with Chemotherapy for the Treatment of Primary Advanced or Recurrent Endometrial Cancer: A Placebo-Controlled Randomized Phase 3 Trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)

Published: April 18, 2023

Mansoor R. Mirza, MD, reviews data from the phase 3 RUBY trial investigating dostarlimab in combination with carboplatin and paclitaxel for the treatment of primary advanced or recurrent endometrial cancer.

Source: onclive.com
Related Topics:
Mansoorr MirzaPrimary AdvancedRecurrent Endometrial CancerPlacebo Controlled Randomized PhaseEndometrial CancerAdvanced Endometrial CancerPrimary Advanced Endometrial CancerPlacebo ControlledEngot En6 NsgoGog 3031Ruby TrialRuby StudyRuby Endometrial CancerRuby Endometrial Carcinoma